TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03431012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agency Assignment framing
Description: Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch...') or the pandemic flu virus itself (VA: 'It can infect you when you touch...')

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agency Assignment framing
Description: Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch...') or the pandemic flu virus itself (VA: 'It can infect you when you touch...')

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agency Assignment framing
Description: Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch...') or the pandemic flu virus itself (VA: 'It can infect you when you touch...')

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agency Assignment framing
Description: Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch...') or the pandemic flu virus itself (VA: 'It can infect you when you touch...')

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attribute framing
Description: Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
Study: NCT01823263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intake task
Description: After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intake task
Description: After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory function task
Description: Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory function task
Description: Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
Study: NCT04437199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricaprilin
Description: Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
Study: NCT00906399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a)
Description: Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a)
Description: Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB017 (peginterferon beta-1a)
Description: Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
Study: NCT01429870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid active treatment
Description: Triamcinolone in unguentum leniens 0.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroid active treatment
Description: Triamcinolone in unguentum leniens 0.1%
Study: NCT03490058

Intervention type: DRUG
Intervention: Truvada
Description: A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
Study: NCT03227991

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention
Description: The Safety Planning Intervention is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings. It involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk factors and Warning signs
Description: Printed information sheet listing suicide risk factors and crisis hotlines
Study: NCT03431012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attribute framing
Description: Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attribute framing
Description: Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
Study: NCT00836004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg capsule
Description: 1 x 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cleocin HCl 300 mg capsules
Description: 1 x 300 mg
Study: NCT05351957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Only dry needling of the lower limbs will performed in all patients with acupunture needling
Study: NCT06321835

Intervention type: PROCEDURE
Intervention: Endotracheal tube cuff pressure measurement
Description: This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough.

Intervention type: PROCEDURE
Intervention: Endotracheal tube cuff pressure measurement
Description: This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough.

Intervention type: PROCEDURE
Intervention: Endotracheal tube cuff pressure measurement
Description: This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough.

Intervention type: PROCEDURE
Intervention: Endotracheal tube cuff pressure measurement
Description: This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough.
Study: NCT01302548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRRISEPT
Description: Device containing sterile water and chlorhexidine gluconate (CHG)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
Study: NCT00729001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPOL
Description: Two-dose intramuscular injection (US subjects only)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPOL
Description: Two-dose intramuscular injection (US subjects only)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IPOL
Description: Two-dose intramuscular injection (US subjects only)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix
Description: Three-dose intramuscular injection (US subjects only)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix
Description: Three-dose intramuscular injection (US subjects only)
Study: NCT03431012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attribute framing
Description: Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
Study: NCT02337842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.4 Challenge Pool CIN-1
Description: Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units.
Study: NCT00729001

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infanrix
Description: Three-dose intramuscular injection (US subjects only)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OmniHIB
Description: Three-dose intramuscular injection (US subjects only)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OmniHIB
Description: Three-dose intramuscular injection (US subjects only)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OmniHIB
Description: Three-dose intramuscular injection (US subjects only)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel
Description: Three-dose intramuscular injection (Canada only)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel
Description: Three-dose intramuscular injection (Canada only)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pentacel
Description: Three-dose intramuscular injection (Canada only)
Study: NCT03664141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: Treatment with cannabis oil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis oil
Description: Treatment with cannabis oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/ Regular Oil
Description: Treatment with placebo (Regular Oil)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/ Regular Oil
Description: Treatment with placebo (Regular Oil)
Study: NCT02092428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image Quality
Description: The following procedures may be conducted as part of this study:~* Coronary MRI scan with no contrast~* Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~* MRI scan with an oral beta blocker (metoprolol)~* Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions.
Study: NCT02092428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Accuracy
Description: Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
Study: NCT03404167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
Study: NCT00943904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interstim implant for SNS
Description: stimulates third sacral nerve root
Study: NCT02337842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.4 Challenge Pool CIN-1
Description: Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.4 Challenge Pool CIN-1
Description: Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration
Study: NCT02927145

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1/ ASO1
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1/ ASO1
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1/ ASO1
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1/ ASO1
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1/ ASO1
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RH5.1/ ASO1
Description: The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity.
Study: NCT05229081

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: vaccine education
Description: The educational content was developed based on research and expert perspectives and included general information about immunization, pneumonia, and pneumococcal vaccines, as well as vaccine myths. This information was first conveyed to the patients verbally, and then booklets with the same material were handed to them. The Pneumococcal Conjugate Vaccine 13 (PCV13) vaccination was recommended based on Infectious Disease Society of America (IDSA), Advisory Committee on Immunization Practices (ACIP), and national adult immunization guidelines.
Study: NCT02337842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration
Study: NCT01013649

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3-dimensional conformal radiation therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study: NCT02504541

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate auto-injector
Description: Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
Study: NCT00109369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information and decision support for providers and patients
Description: Laboratory-based decision support, reminders, and population report cards.
Study: NCT01625767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAT experiment
Description: Smokers and nonsmokers complete AAT experiment
Study: NCT00899457

Intervention type: GENETIC
Intervention: proteomic profiling
Description: Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
Study: NCT01013649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study: NCT00899457

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath

Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: Collection of breath condensate.
Study: NCT02242006

Intervention type: OTHER
Intervention: serial serum sampling for quantification of drug concentration

Intervention type: OTHER
Intervention: serial serum sampling for quantification of drug concentration
Study: NCT01013649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Given combination chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given combination chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given combination chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT02242006

Intervention type: OTHER
Intervention: serial serum sampling for quantification of drug concentration